CEN Biotech (CEN Biotech) Risk Assessment

View and export this data going back to 2016. Start your Free Trial

What is CEN Biotech Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of CEN Biotech is: No Data: Cannot be evaluated.

Competitive Comparison of CEN Biotech's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEN Biotech's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's Risk Assessment distribution charts can be found below:

* The bar in red indicates where CEN Biotech's Risk Assessment falls into.

CEN Biotech (OTCPK:CENBF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

CEN Biotech Risk Assessment Related Terms

Thank you for viewing the detailed overview of CEN Biotech's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

CEN Biotech (CEN Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CEN Biotech Inc (OTCPK:CENBF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9

Website

CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.

Executives

Lawrence Lehoux	director, officer: Chief Technology Officer	11879 SOLOMAN ST, WINDSOR A6 N8P 1P1
Jeffery Allen Thomas	director	23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183
Rick Leigh Purdy	director	9 ELAINE STREET, ST. ALBERT A0 T8N7R6
Usamakh Saadikh	director	3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210
Joseph A. Byrne	director, officer: Chief Executive Officer	6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5
Alex Tarrabain	director	18908 89 AVENUE, EDMONTON A0 T5T 6B7
Donald Strilchuck	director	352 RIDEAU PL, TECUMSEH A6 N8N 3N9
Richard Boswell	director, 10 percent owner, officer: CFO Senior Executive VP	2408 EASTERN AVE., ROCHESTER HILLS MI 48307
Ameen Ferris	director	30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6
Brian Payne	director, officer: Vice President	1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0
Aubrey De Lavenu Harold Andre	director	APT 627 VALE DO LOBO, ALMANCIL S1 8135-034
Bahige B. Chaaban	director, 10 percent owner, officer: Chief Executive Officer	888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0

CEN Biotech (CEN Biotech) Headlines

From GuruFocus

CEN Biotech Inc. Announces Planned Strategic Expansion of Business and Closing of Clear Com Media Inc. Acquisition

By ACCESSWIRE ACCESSWIRE • 07-13-2021

CEN Biotech Inc. Announces Word Presto Partner Program

By ACCESSWIRE ACCESSWIRE • 11-08-2022